{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:13Z","timestamp":1788966073230,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00228-024-03778-3","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T06:19:08Z","timestamp":1732342748000},"page":"203-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the safety and effectiveness of tolvaptan in patients with heart failure and renal impairment: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"81","author":[{"given":"Aashish","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafin Bin","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Ali","family":"Arsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad Sinaan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ashir","family":"Shafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Saad","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimen","family":"Naz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emediong Santhus","family":"Asuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"issue":"45","key":"3778_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035900","volume":"102","author":"J Yang","year":"2023","unstructured":"Yang J, Zhang L, Guo M, Hao M (2023) Effects of recombinant human brain natriuretic peptide combined with tolvaptan on cardiac and renal function and serum inflammatory factors in patients with severe heart failure. Medicine 102(45):e35900","journal-title":"Medicine"},{"key":"3778_CR2","first-page":"7","volume":"80","author":"W Urbaszek","year":"1991","unstructured":"Urbaszek W (1991) Definition und klassifikation der herzinsuffizienz. Zeitschrift f\u00fcr Kardiologie 80:7\u201312","journal-title":"Zeitschrift f\u00fcr Kardiologie"},{"issue":"2","key":"3778_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00041552-200403000-00004","volume":"13","author":"D Silverberg","year":"2004","unstructured":"Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A (2004) The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 13(2):163\u2013170","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"3778_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.medcli.2013.04.027","volume":"142","author":"JC Trull\u00e0s","year":"2013","unstructured":"Trull\u00e0s JC, Morales-Rull JL, Formiga F (2013) Diuretic therapy in heart failure. Med Clin 142(4):163\u2013170","journal-title":"Med Clin"},{"issue":"10","key":"3778_CR5","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","volume":"9","author":"V Hasselblad","year":"2007","unstructured":"Hasselblad V, Stough WG, Shah MR, Lokhnygina Y, O\u2019Connor CM, Califf RM, Adams KF Jr (2007) Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 9(10):1064\u20131069","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"3778_CR6","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3390\/jcm3041276","volume":"3","author":"PR Bhatt","year":"2014","unstructured":"Bhatt PR, McNeely EB, Lin TE, Adams KF Jr, Patterson JH (2014) Review of tolvaptan\u2019s pharmacokinetic and pharmacodynamic properties and drug interactions. J Clin Med 3(4):1276\u20131290","journal-title":"J Clin Med"},{"issue":"4","key":"3778_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.hfc.2014.07.009","volume":"10","author":"TE Lin","year":"2014","unstructured":"Lin TE, Adams KF, Patterson JH (2014) Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients. Heart Fail Clin 10(4):607\u2013620","journal-title":"Heart Fail Clin"},{"issue":"6","key":"3778_CR8","first-page":"1149","volume":"4","author":"MB Dixon","year":"2008","unstructured":"Dixon MB, Lien YH (2008) Tolvaptan and its potential in the treatment of hyponatremia. Ther Clin Risk Manag 4(6):1149\u20131155","journal-title":"Ther Clin Risk Manag"},{"key":"3778_CR9","doi-asserted-by":"publisher","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) Cochrane bias methods group; cochrane statistical methods group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","DOI":"10.1136\/bmj.d5928"},{"issue":"11","key":"3778_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"issue":"7","key":"3778_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2459\/JCM.0b013e328355a740","volume":"13","author":"M Vaduganathan","year":"2012","unstructured":"Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C (2012) Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J Cardiovasc Med 13(7):415\u2013422","journal-title":"J Cardiovasc Med"},{"issue":"5","key":"3778_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","volume":"67","author":"K Kimura","year":"2016","unstructured":"Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U (2016) Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 67(5):399\u2013405. https:\/\/doi.org\/10.1016\/j.jjcc.2015.09.020","journal-title":"J Cardiol"},{"issue":"6","key":"3778_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","volume":"22","author":"Y Matsue","year":"2016","unstructured":"Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR (2016) Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 22(6):423\u2013432. https:\/\/doi.org\/10.1016\/j.cardfail.2016.02.007","journal-title":"J Card Fail"},{"issue":"5","key":"3778_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1253\/circj.CJ-16-1122","volume":"81","author":"S Tamaki","year":"2017","unstructured":"Tamaki S, Sato Y, Yamada T, Morita T, Furukawa Y, Iwasaki Y, Kawasaki M, Kikuchi A, Kondo T, Ozaki T, Seo M, Ikeda I, Fukuhara E, Abe M, Nakamura J, Fukunami M (2017) Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction - prospective randomized controlled study. Circ J 81(5):740\u2013747. https:\/\/doi.org\/10.1253\/circj.CJ-16-1122","journal-title":"Circ J"},{"issue":"4","key":"3778_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1536\/ihj.16-438","volume":"58","author":"H Nomoto","year":"2017","unstructured":"Nomoto H, Satoh Y, Kamiyama M, Yabe K, Masumura M, Sakakibara A, Yamashita S, Suzuki M, Sugiyama T, Oumi T, Ohno M, Takahashi Y, Isobe M (2017) Mechanisms of diuresis for acute decompensated heart failure by tolvaptan. Int Heart J 58(4):593\u2013600. https:\/\/doi.org\/10.1536\/ihj.16-438","journal-title":"Int Heart J"},{"issue":"5","key":"3778_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1159\/000481995","volume":"46","author":"N Tominaga","year":"2017","unstructured":"Tominaga N, Kida K, Inomata T, Sato N, Izumi T, Akashi YJ, Shibagaki Y (2017) Effects of tolvaptan addition to furosemide in normo- and hyponatremia patients with heart failure and chronic kidney disease stages G3b\u20135: a subanalysis of the K-STAR study. Am J Nephrol 46(5):417\u2013426. https:\/\/doi.org\/10.1159\/000481995","journal-title":"Am J Nephrol"},{"issue":"9","key":"3778_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10157-022-02224-x","volume":"26","author":"S Komiya","year":"2022","unstructured":"Komiya S, Katsumata M, Ozawa M, Haze T, Kawano R, Ohki Y, Suzuki S, Kobayashi Y, Fujiwara A, Saka S (2022) Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial. Clin Exp Nephrol 26(9):851\u2013858","journal-title":"Clin Exp Nephrol"},{"key":"3778_CR18","doi-asserted-by":"publisher","first-page":"B38","DOI":"10.1093\/eurheartj\/suz027","volume":"21","author":"G Cice","year":"2019","unstructured":"Cice G (2019) Renal insufficiency in acute heart failure: old habits we need to let go? Eur Heart J Suppl 21:B38\u2013B42","journal-title":"Eur Heart J Suppl"},{"issue":"10","key":"3778_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrneph.2016.113","volume":"12","author":"JC Schefold","year":"2016","unstructured":"Schefold JC, Filippatos G, Hasenfuss G, Anker SD, Von Haehling S (2016) Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol 12(10):610\u2013623","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"3778_CR20","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.jacc.2005.11.084","volume":"47","author":"GL Smith","year":"2006","unstructured":"Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM (2006) Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 47(10):1987\u20131996","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"3778_CR21","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2215\/CJN.14180920","volume":"16","author":"D Banerjee","year":"2021","unstructured":"Banerjee D, Rosano G, Herzog CA (2021) Management of heart failure patient with CKD. Clin J Am Soc Nephrol 16(7):1131\u20131139","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"3778_CR22","first-page":"101","volume":"8","author":"D Masarone","year":"2021","unstructured":"Masarone D, Martucci ML, Errigo V, Pacileo G (2021) The use of \u03b2-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis 8(9):101","journal-title":"J Cardiovasc Dev Dis"},{"issue":"10","key":"3778_CR23","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1093\/ckj\/sfab029","volume":"14","author":"TJ Humphrey","year":"2021","unstructured":"Humphrey TJ, James G, Wittbrodt ET, Zarzuela D, Hiemstra TF (2021) Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD). Clin Kidney J 14(10):2203\u20132212","journal-title":"Clin Kidney J"},{"issue":"2","key":"3778_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0167-5273(01)00600-3","volume":"82","author":"R Faris","year":"2002","unstructured":"Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A (2002) Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 82(2):149\u2013158","journal-title":"Int J Cardiol"},{"issue":"10","key":"3778_CR25","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","volume":"75","author":"GM Felker","year":"2020","unstructured":"Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM (2020) Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol 75(10):1178\u20131195","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3778_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","volume":"26","author":"TA McDonagh","year":"2024","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J (2024) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur\u00a0J Heart Fail 26(1):5\u201317","journal-title":"Eur\u00a0J Heart Fail"},{"issue":"2","key":"3778_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WW, Orso F, Rossignol P (2019) The use of diuretics in heart failure with congestion\u2014a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(2):137\u2013155","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"3778_CR28","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136(6):e137\u2013e161","journal-title":"Circulation"},{"issue":"11","key":"3778_CR29","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1253\/circj.CJ-17-0554","volume":"81","author":"Y Uemura","year":"2017","unstructured":"Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Imai R, Ozaki Y, Watanabe T, Teraoka T (2017) Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease. Circ J 81(11):1736\u20131738","journal-title":"Circ J"},{"key":"3778_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-017-0598-y","volume":"17","author":"C Wang","year":"2017","unstructured":"Wang C, Xiong B, Cai L (2017) Effects of tolvaptan in patients with acute heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord 17:1\u201311","journal-title":"BMC Cardiovasc Disord"},{"key":"3778_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10741-015-9503-x","volume":"20","author":"B Xiong","year":"2015","unstructured":"Xiong B, Huang Y, Tan J, Yao Y, Wang C, Qian J, Rong S, Deng S, Cao Y, Zou Y (2015) The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev 20:633\u2013642","journal-title":"Heart Fail Rev"},{"key":"3778_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10557-011-6304-x","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, Fukunami M, Investigators T (2011) Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25:33\u201345","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"3778_CR33","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.hlc.2017.12.013","volume":"27","author":"J Sen","year":"2018","unstructured":"Sen J, Chung E, McGill D (2018) Tolvaptan for heart failure in chronic kidney disease patients: a systematic review and meta-analysis. Heart Lung Circ 27(8):928\u2013939","journal-title":"Heart Lung Circ"},{"issue":"1","key":"3778_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","volume":"82","author":"T Inomata","year":"2017","unstructured":"Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, Shinagawa H, Ako J, Izumi T, Investigators KA (2017) Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment-results from the K-STAR study-. Circ J 82(1):159\u2013167","journal-title":"Circ J"},{"issue":"4","key":"3778_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40801-022-00325-3","volume":"9","author":"K Uchiyama","year":"2022","unstructured":"Uchiyama K, Kojima D, Hama EY, Nagasaka T, Nakayama T, Takahashi R, Tajima T, Morimoto K, Washida N, Itoh H (2022) Effect of tolvaptan in patients with chronic kidney disease stage G5, and impact of concomitant use of thiazide diuretics: a retrospective cohort study. Drugs-Real World Outcomes 9(4):649\u2013657","journal-title":"Drugs-Real World Outcomes"},{"issue":"3","key":"3778_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ehf2.12088","volume":"3","author":"K Jujo","year":"2016","unstructured":"Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, Sekiguchi H, Yamaguchi J, Ogawa H, Hagiwara N (2016) Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 3(3):177\u2013188","journal-title":"ESC Heart Fail"},{"key":"3778_CR37","unstructured":"Arumugham VB, Shahin MH (2023) Therapeutic Uses of Diuretic Agents. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL"},{"issue":"1","key":"3778_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2125.2011.04029.x","volume":"73","author":"EA Dubois","year":"2012","unstructured":"Dubois EA, Rissmann R, Cohen AF (2012) Tolvaptan. Br J Clin Pharmacol 73(1):9","journal-title":"Br J Clin Pharmacol"},{"key":"3778_CR39","doi-asserted-by":"publisher","first-page":"175394472097774","DOI":"10.1177\/1753944720977741","volume":"15","author":"J Urbach","year":"2021","unstructured":"Urbach J, Goldsmith SR (2021) Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials. Ther Adv Cardiovasc Dis 15:1753944720977741. https:\/\/doi.org\/10.1177\/1753944720977741","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"12","key":"3778_CR40","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 297(12):1332\u20131343. https:\/\/doi.org\/10.1001\/jama.297.12.1332","journal-title":"JAMA"},{"issue":"7\u20138","key":"3778_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000531692","volume":"54","author":"T Tagaya","year":"2023","unstructured":"Tagaya T, Hayashi H, Ogata S, Takahashi K, Koide S, Inaguma D, Hasegawa M, Yuzawa Y, Tsuboi N (2023) Tolvaptan\u2019s association with low risk of acute kidney injury in patients with advanced chronic kidney disease and acute decompensated heart failure. Am J Nephrol 54(7\u20138):319\u2013328","journal-title":"Am J Nephrol"},{"issue":"4","key":"3778_CR42","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1253\/circj.CJ-13-1255","volume":"78","author":"A Shirakabe","year":"2014","unstructured":"Shirakabe A, Hata N, Yamamoto M, Kobayashi N, Shinada T, Tomita K, Tsurumi M, Matsushita M, Okazaki H, Yamamoto Y (2014) Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J 78(4):911\u2013921","journal-title":"Circ J"},{"issue":"23","key":"3778_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015987","volume":"98","author":"L Shi","year":"2019","unstructured":"Shi L, Lin L (2019) The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine 98(23):e15987","journal-title":"Medicine"},{"key":"3778_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-14-70","volume":"14","author":"WA van Enst","year":"2014","unstructured":"van Enst WA, Ochodo E, Scholten RJ, Hooft L, Leeflang MM (2014) Investigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study. BMC Med Res Methodol 14:1\u201311","journal-title":"BMC Med Res Methodol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03778-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03778-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03778-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T08:06:59Z","timestamp":1736410019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03778-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3778"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03778-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,23]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}